The Clinical Characteristics of Psoriatic Arthritis: A Cross-Sectional Study Based on the Psoriatic Arthritis Cohort of West China Hospital
ConclusionOur study proposes that the prevalent population of PsA are male patients with psoriasis over 40 years of age who have a long disease course. For patients with PsA, MCP, PIP joints of fingers, and sacroiliac joints are the most frequently affected anatomical sites. With respect to comorbidities, the association between PsA and fatty liver and the underlying molecular mechanisms are worthy of further exploration. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 16, 2023 Category: Rheumatology Source Type: research
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
ConclusionsIn adjusted analyses, CCP+ patients with RA initiating treatment with abatacept versus tofacitinib did not show a statistically significant difference in reducing disease activity or improving patient-reported outcomes. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 7, 2023 Category: Rheumatology Source Type: research
Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study
ConclusionThere were substantial clinical burden and healthcare costs among patients with SLE in the 12 months pre-ESKD diagnosis. The clinical burden and healthcare costs generally increased with each year approaching ESKD diagnosis. Early interventions for patients with SLE could prevent the development of ESKD, mitigating the burden of the disease. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 4, 2023 Category: Rheumatology Source Type: research
Trends in Hospitalization for Tuberculosis and Other Opportunistic Infections in Australian Patients with Inflammatory Joint Diseases
ConclusionsDespite decreasing admission rates for tuberculosis and pneumocystosis in RA patients, an overall increase in mycotic and viral infection rates over time was seen across all three IJD. Together with a significant case fatality rate, this indicates continued efforts are needed to improve OI prevention in the management of IJD patients. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 4, 2023 Category: Rheumatology Source Type: research
Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
ConclusionIn the MAIC and STC analyses from TARGET and SELECT-BEYOND trials, the efficacy of sarilumab and upadacitinib were comparable. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2023 Category: Rheumatology Source Type: research
High Usability and Applicability Ratings for the New SmartClic ®/ClicWise® Injection Device: Evidence from a Health Care Professional Opinion Study
ConclusionsInitial feedback from HCPs on the SmartClic/ClicWise device and proposed app was generally favorable, suggesting they will provide an acceptable alternative for self-administration of biologics for patients with rheumatoid arthritis and other chronic conditions. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 22, 2023 Category: Rheumatology Source Type: research
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
ConclusionIn patients receiving baricitinib 4-mg, lower baseline CDAI was generally associated with rapid response, while higher baseline CDAI scores were generally seen for patients who either reached treatment targets more gradually, or who had a partial or limited response. Maintenance of response was observed with continued baricitinib treatment in all response groups and generally included maintenance of mTSS. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 20, 2023 Category: Rheumatology Source Type: research
Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study
ConclusionBelimumab treatment for up to 2 years improved clinical outcomes, disease severity, mean OCS dose and HCRU in US African American and Hispanic patients with SLE, providing real-world evidence for enduring belimumab effectiveness in populations that are markedly impacted by SLE. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 18, 2023 Category: Rheumatology Source Type: research
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
ConclusionIn the overall matched population, CZP performed significantly better than most comparators in improving the clinical outcomes. Among patients with OSI, CZP was found to be superior to SEC (in the MRI −/CRP + and MRI + /CRP− subgroups) and ETN (in the MRI + /CRP− subgroup) and it was comparable to golimumab and IXE across the different OSI subgroups. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 12, 2023 Category: Rheumatology Source Type: research
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch —A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
ConclusionsNon-medical switching in RA treatment may lead to unforeseen outcomes that should be considered by health decision-makers. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 12, 2023 Category: Rheumatology Source Type: research
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
ConclusionsThe degrees of disease activity improvement at 3 months independently predicted the subsequent GC withdrawal. These findings suggest the importance of dynamic treatment strategies with a closer look at disease activity during GC tapering and discontinuation. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 6, 2023 Category: Rheumatology Source Type: research
Number of Attending Physicians and Accumulated Organ Damage in Patients with Systemic Lupus Erythematosus: LUNA Registry Cross-Sectional Study
ConclusionsThis study showed that SDI could increase as the number of attending physicians increases. The impact of changing attending physicians warrants greater attention for SLE and other diseases. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 6, 2023 Category: Rheumatology Source Type: research
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 4, 2023 Category: Rheumatology Source Type: research
PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
AbstractIntroductionRandomised clinical studies in psoriatic arthritis (PsA) do not always reflect patients in routine clinical practice. Large-scale data from routine practice are needed to better understand drug persistence, effectiveness and long-term safety of therapeutic agents.MethodsPsABIOnd is an international, prospective, observational study designed to collect long-term routine care data in patients with PsA who receive guselkumab (an interleukin-23 [IL-23] inhibitor) or an interleukin-17 (IL-17) inhibitor. Adult patients ( ≥ 18 years) with a confirmed diagnosis of PsA who are starting guselkumab or any app...
Source: Rheumatology and Therapy - December 30, 2022 Category: Rheumatology Source Type: research
Serious Infection Rates Among Patients with Select Autoimmune Conditions: A Claims-Based Retrospective Cohort Study from Taiwan and the USA
ConclusionThis study identified a significant excess serious infection burden among patients with targeted autoimmune conditions compared with the general populations in Taiwan and the USA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 26, 2022 Category: Rheumatology Source Type: research
